Effects of Recombinant Human Growth Hormone on Body Composition and Metabolism in HIV-Associated Wasting

  • K. Mulligan
  • C. Grunfeld
  • M. K. Hellerstein
  • R. A. Neese
  • M. Schambelan
Conference paper
Part of the Serono Symposia USA book series (SERONOSYMP)

Abstract

Body wasting is a frequent and potentially devastating accompaniment to infection with human immunodeficiency virus (HIV). Wasting can impair functional performance, immune function, and quality of life and is a factor in survival itself (1, 2). In many patients infected with HIV, death occurs when body cell mass (BCM) is depleted below a level that is critical to sustain life (1), implying that death in these patients may be due to malnutrition per se, rather than to the direct effects of infection and malignancy. The demonstrated associations between loss of body weight or BCM and survival imply that maintenance or restoration of weight or BCM could prolong life in HIV-infected persons (1). Thus, considerable effort has been directed to the search for effective anabolic therapies.

Keywords

Obesity Glycerol Urea Carbohydrate Lactate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kotler DP, Tierney AR, Wang J, Pierson RN Jr. Magnitude of body-cellmass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 1989;50:444–7.PubMedGoogle Scholar
  2. 2.
    Chlebowski RT, Grosvenor MB, Bernhard NH, Morales LS, Bulcavage LM. Nutritional status, gastrointestinal dysfunction, and survival in patients with AIDS. Am J Gastroenterol 1989;84:1288–93.PubMedGoogle Scholar
  3. 3.
    Kotler DP, Tierney AR, Ferraro R, et al. Enteral alimentation and repletion of body cell mass in malnourished patients with acquired immunodeficiency syndrome. Am J Clin Nutr 1991;53:149–54.PubMedGoogle Scholar
  4. 4.
    Kotler DP, Tierney AR, Culpepper-Morgan JA, Wang J, Pierson RN Jr. Effect of home total parenteral nutrition on body composition in patients with acquired immunodeficiency syndrome. J Parenter Enteral Nutr 1990;14: 454–8.CrossRefGoogle Scholar
  5. 5.
    Struwe M, Kaempfer SH, Geiger CJ, et al. Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother 1993;27:827–31.PubMedGoogle Scholar
  6. 6.
    Von Roenn JH, Roth EL, Craig R. HIV-related cachexia: potential mechanisms and treatment. Oncology 1992;49(suppl 2):50–4.CrossRefGoogle Scholar
  7. 7.
    Hellerstein MK, Kahn J, Mudie H, Viteri F. Current approach to the treatment of human immunodeficiency virus-associated weight loss: pathophysiologic considerations and emerging management strategies. Semin Oncol 1990;17(suppl 9):17–33.PubMedGoogle Scholar
  8. 8.
    Summerbell CD, Youl M, McDonald V, Catalan J, Gazzard BG. Megestrol acetate vs cyproheptadine in the treatment of weight loss associated with HIV infection. Int J STD and AIDS 1992;3:278–80.Google Scholar
  9. 9.
    Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD. Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 1993;11:152–4.PubMedGoogle Scholar
  10. 10.
    Hommes MJT, Romijn JA, Endert E, Sauerwein HP. Resting energy expenditure and substrate oxidation in human immunodeficiency virus (HIV)-infected asymptomatic men: HIV affects host metabolism in the early asymptomatic stage. Am J Clin Nutr 1991;54:311–5.PubMedGoogle Scholar
  11. 11.
    Hommes MJT, Romijn JA, Endert E, Eeftinck-Schattenkerk JKM, Sauerwein HP. Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism 1991;40:651–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Ward HC, Halliday D, Sim AJW. Protein and energy metabolism with biosynthetic human growth hormone after gastrointestinal surgery. Ann Surg 1987;206:56–61.PubMedCrossRefGoogle Scholar
  13. 13.
    Ziegler TR, Young LS, Ferrari-Baliviera E, Demling RH, Wilmore DW. Use of human growth hormone combined with nutritional support in a critical care unit. J Parenter Enteral Nutr 1990;14:574–81.CrossRefGoogle Scholar
  14. 14.
    Tayek JA, Brasel JA. Growth hormone administration decreases urea nitrogen losses in malnourished cancer patients. Clin Res 1992;40:95A.Google Scholar
  15. 15.
    Manson JMcK, Wilmore DW. Positive nitrogen balance with human growth hormone and hypocaloric intravenous feeding. Surgery 1986;100:188–97.PubMedGoogle Scholar
  16. 16.
    Mulligan K, Grunfeld C, Hellerstein MK, Neese RA, Schambelan M. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1993;77:956–62.PubMedCrossRefGoogle Scholar
  17. 17.
    Society of actuaries and association of life insurance medical directors of America: 1979 build study. New York: Metropolitan Life Insurance, 1989: 127.Google Scholar
  18. 18.
    Harris J, Benedict F. A biometric study of basal metabolism in man. Washington, DC: Carnegie Instit Pub 279:1919.Google Scholar
  19. 19.
    Ferrannini E. The theoretical bases of indirect calorimetry: a review. Metabolism 1988;3:287–301.CrossRefGoogle Scholar
  20. 20.
    Segal KR, Van Loan M, Fitzgerald PI, Hodgdon JA, Van Itallie TB. Lean body mass estimation by bioelectrical impedance analysis: a four-site cross-validation study. Am J Clin Nutr 1988;47:7–14.PubMedGoogle Scholar
  21. 21.
    Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74:1045–52.PubMedCrossRefGoogle Scholar
  22. 22.
    Wolfe RR. Tracers in metabolic research. Radioisotope and stable isotope/ mass spectrometry methods. New York: Alan R. Liss, 1984.Google Scholar
  23. 23.
    Hellerstein MK, Christiansen M, Kaempfer S, et al. Measurement of de novo hepatic lipogenesis in humans using stable isotopes. J Clin Invest 1991;87: 1841–52.PubMedCrossRefGoogle Scholar
  24. 24.
    Forster HV, Dempsey JA, Thomson J, Vidruk E, doPico GA. Estimation of arterial pO2, pCO2, pH, and lactate from arterialized venous blood. J Appl Physiol 1972;32:134–7.PubMedGoogle Scholar
  25. 25.
    Hellerstein MK. Relationship between precursor enrichment and ratio of excess M2/excess M1 isotopomer frequencies in a secreted polymer. J Biol Chem 1991;266:10920–4.PubMedGoogle Scholar
  26. 26.
    Forbes GB. Body composition: influence of nutrition, disease, growth and aging. In: Shils ME, Young VR, eds. Modern nutrition in health and disease. 7th ed. Philadelphia: Lea and Febiger, 1988:533–56.Google Scholar
  27. 27.
    Krentz AJ, Koster FT, Crist DM, et al. Anthropometric, metabolic, and immunological effects of recombinant human growth hormone in AIDS and AIDS-related complex. J AIDS 1993;6:245–51.Google Scholar
  28. 28.
    Farber SJ, Schubert M. The binding of cations by chondroitin sulfate. J Clin Invest 1957;36:1715–22.PubMedCrossRefGoogle Scholar
  29. 29.
    Mulligan K, Grunfeld C. Nutrition in HIV infection—an update. Curr Opin Gastroenterol 1994.Google Scholar
  30. 30.
    Hellerstein MK, Grunfeld C, Wu K, et al. Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J Clin Endocrinol Metab 1993;76:559–65.PubMedCrossRefGoogle Scholar
  31. 31.
    Waterhouse C, Jeanpretre N, Keilson J. Gluconeogenesis from alanine in patients with progressive malignant disease. Cancer Res 1979;39:1968–72.PubMedGoogle Scholar
  32. 32.
    Melchior J-C, Salmon D, Rigaud D, et al. Resting energy expenditure is increased in stable, malnourished HIV-infected patients. Am J Clin Nutr 1991;53:437–41.PubMedGoogle Scholar
  33. 33.
    Grunfeld C, Pang M, Shimizu L, Shigenaga JK, Jensen P, Feingold KR. Resting energy expenditure, caloric intake and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Am J Clin Nutr 1992;55:455–60.PubMedGoogle Scholar
  34. 34.
    Melchior J-C, Raguin G, Boulier A, et al. Resting energy expenditure in human immunodeficiency virus-infected patients: comparison between patients with and without secondary infections. Am J Clin Nutr 1993;57:614–9.PubMedGoogle Scholar
  35. 35.
    Macallan DC, Noble C, Baldwin C, Foskett M, McManus T, Griffin GE. Prospective analysis of patterns of weight change in stage IV HIV infection. Am J Clin Nutr 1993;58:417–24.PubMedGoogle Scholar
  36. 36.
    Klein S, Wolfe R. Whole-body lipolysis and triglyceride-fatty acid cycling in cachectic patients with esophageal cancer. J Clin Invest 1990;86:1403–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Flatt J-P. The biochemistry of energy expenditure. In: Recent advances in obesity research; vol II. Westport, CT: Technomic Publishing, 1979:211–28.Google Scholar
  38. 38.
    D’Ercole AJ, Stiles AD, Underwood LE. Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci USA 1984;81:935–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • K. Mulligan
  • C. Grunfeld
  • M. K. Hellerstein
  • R. A. Neese
  • M. Schambelan

There are no affiliations available

Personalised recommendations